Loading institutional data...
Loading institutional data...
Held by 350 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
Free-cash-flow coverage unavailable. Last year: $60M dividends + $300M buybacks = $360M returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -16%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $379M covers the $50M due within a year 7.6× over. Scheduled principal only (excludes interest & revolver draws). As of 2019-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~3.8% on $2.6B of debt.
Cash of $379M fully covers short-term debt of $100M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.99B 100.0% | $1.70B 100.0% | $1.71B 100.0% | $2.79B 100.0% | $2.81B 100.0% | $2.54B 100.0% | $2.60B 100.0% | $2.45B 100.0% | $2.15B 100.0% | $1.87B 100.0% |
| Cost of Revenue | $872.0M 43.8% | $662.2M 39.0% | $672.3M 39.3% | $1.26B 45.1% | $1.26B 44.8% | $1.21B 47.8% | $1.19B 45.7% | $1.15B 46.8% | $974.5M 45.4% | $871.8M 46.7% |
| Cost of Products | — | — | — | — | — | — | — | — | $974.5M 45.4% | $871.8M 46.7% |
| Gross Profit | $1.12B 56.2% | $1.04B 61.0% | $1.04B 60.7% | $1.53B 54.9% | $1.55B 55.2% | $1.32B 52.2% | $1.41B 54.3% | $1.30B 53.2% | $1.17B 54.6% | $996.2M 53.3% |
| Research & Development | $144.8M 7.3% | $109.0M 6.4% | $113.6M 6.6% | $153.8M 5.5% | $130.8M 4.7% | $119.7M 4.7% | $113.9M 4.4% | $106.2M 4.3% | $84.8M 3.9% | $58.6M 3.1% |
| Selling, General & Admin | $720.2M 36.1% | $674.5M 39.7% | $622.7M 36.4% | $863.7M 30.9% | $860.1M 30.6% | $743.6M 29.3% | $851.8M 32.8% | $797.1M 32.6% | $700.0M 32.6% | $563.3M 30.2% |
| Operating Income | $118.4M 5.9% | $103.7M 6.1% | $258.7M 15.1% | $499.7M 17.9% | $628.1M 22.4% | $423.1M 16.7% | $427.3M 16.5% | $321.7M 13.1% | $372.3M 17.3% | $319.5M 17.1% |
| Interest Expense | $100.2M 5.0% | $83.5M 4.9% | $85.1M 5.0% | $54.3M 1.9% | $57.0M 2.0% | $66.5M 2.6% | $80.3M 3.1% | $103.0M 4.2% | $82.5M 3.8% | $54.9M 2.9% |
| Interest & Investment Income | $6.4M 0.3% | $6.2M 0.4% | $11.7M 0.7% | $912K 0.0% | $1.3M 0.0% | $1.2M 0.0% | $1.7M 0.1% | $944K 0.0% | $771K 0.0% | $474K 0.0% |
| Pretax Income | $24.6M 1.2% | $26.3M 1.5% | $185.4M 10.8% | $445.9M 16.0% | $559.5M 19.9% | $357.7M 14.1% | $339.9M 13.1% | $219.6M 9.0% | $284.9M 13.3% | $245.7M 13.2% |
| Income Tax Expense | -$34.0M -1.7% | -$30.9M -1.8% | $41.9M 2.4% | $83.0M 3.0% | $74.3M 2.6% | $21.9M 0.9% | -$122.1M -4.7% | $23.2M 0.9% | $129.6M 6.0% | $8.1M 0.4% |
| Net Income | -$905.6M -45.4% | $70.2M 4.1% | $357.6M 20.9% | $363.1M 13.0% | $485.4M 17.3% | $335.3M 13.2% | $461.5M 17.8% | $200.8M 8.2% | $152.5M 7.1% | $237.4M 12.7% |
| Per Share | ||||||||||
| EPS (Basic) | $-20.30 | $1.49 | $7.58 | $7.74 | $10.38 | $7.21 | $9.99 | $4.39 | $3.39 | $5.48 |
| EPS (Diluted) | $-20.25 | $1.48 | $7.53 | $7.68 | $10.23 | $7.09 | $9.80 | $4.29 | $3.27 | $4.98 |
| Weighted Avg Shares (Basic) | 44.6M | 46.8M | 47.0M | 46.9M | 46.8M | 46.5M | 46.2M | 45.7M | 45.0M | 43.3M |
| Weighted Avg Shares (Diluted) | 44.7M | 47.1M | 47.3M | 47.3M | 47.4M | 47.3M | 47.1M | 46.8M | 46.7M | 47.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 45th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 46.8 | 45.7 | 47.8 | 44.8 | 45.1 | 39.3 | 39.0 | 43.8 |
| Gross Profit | 53.2 | 54.3 | 52.2 | 55.2 | 54.9 | 60.7 | 61.0 | 56.2 |
| R&D | 4.3 | 4.4 | 4.7 | 4.7 | 5.5 | 6.6 | 6.4 | 7.3 |
| SG&A | 32.6 | 32.8 | 29.3 | 30.6 | 30.9 | 36.4 | 39.7 | 36.1 |
| Operating Income | 13.1 | 16.5 | 16.7 | 22.4 | 17.9 | 15.1 | 6.1 | 5.9 |
| Income Tax | 0.9 | -4.7 | 0.9 | 2.6 | 3.0 | 2.4 | -1.8 | -1.7 |
| Net Income | 8.2 | 17.8 | 13.2 | 17.3 | 13.0 | 20.9 | 4.1 | -45.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on TFX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| TFX | $5.6B | — | 45.1× | 2.8× | 17.2% | 56.2% | -45.4% | -29.0% | -15.7% | 15.1× | 350 |
Peers = companies sharing TFX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.